NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Rohit Gosain/LinkedIn
Oct 27, 2025, 08:00

Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation

Rohit Gosain, Medical Director of Roswell Park Comprehensive Cancer Center, posted on LinkedIn:

“Revumenib is now FDA approved for R/R AML with NPM1 mutation (approved for KMT2A translocation previously).

– ORR 46.9%
– Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx).”

Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation

Stay informed with Hemostasis Today.

FDA Headlines Health Hematology Hemostasis Hemostasis Today Medicine R/R AML w/ NPM1 Mutation Revumenib Rohit Gosain
NewsFeed